PBDs

By Targets:	ADC Cytotoxin (8) ADC Linker (1) Amyloid-β (1) Antibiotic (3) Apoptosis (1) Autophagy (1) Bacterial (9) Cholecystokinin Receptor (1) DNA Alkylator/Crosslinker (6) DNA/RNA Synthesis (1) Drug-Linker Conjugates for ADC (5) Isotope-Labeled Compounds (2) Polo-like Kinase (PLK) (1) TAM Receptor (1)
By Research Areas:	Cancer (21) Infection (4) Neurological Disease (1)
Click Chemistry:	DBCO (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101161

SG3199 2 Publications Verification	DNA Alkylator/Crosslinker ADC Cytotoxin	Cancer
SG3199 is a cytotoxic DNA minor groove interstrand crosslinking pyrrolobenzodiazepine (PBD) dimer. SG3199 is the released warhead component of the ADC payload Tesirine (SG3249) .

HY-101160

SG2057 DRG16	DNA Alkylator/Crosslinker ADC Cytotoxin	Cancer
SG2057 (DRG16) is a PBD dimer containing a pentyldioxy linkage which binds sequence selectively in the minor groove of DNA forming DNA interstrand and intrastrand cross-linked adducts. SG2057 is a highly active antitumor agent .

HY-128952

Tesirine 2 Publications Verification SG3249	Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker	Cancer
Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity .

HY-161252

PBD-monoamide	ADC Cytotoxin	Cancer
PBD-monoamide, a modified PBD (pyrrolobenzodiazepine) dimer, is an ADC Cytotoxin. PBD-monoamide can be used for synthesis of DHES0815A (an HER2 ADC). PBD-monoamide has DNA-binding activity and reduces cell viability .

HY-135900

Aniline-MPB-amino-C3-PBD	ADC Cytotoxin Bacterial	Cancer
Aniline-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Aniline-MPB-amino-C3-PBD is a sequence-selective DNA minor-groove binding agent. Aniline-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .

HY-P99734

Mipasetamab uzoptirine ADCT-601	TAM Receptor	Cancer
Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers .

HY-135901

Py-MPB-amino-C3-PBD	ADC Cytotoxin Bacterial	Cancer
Py-MPB-amino-C3-PBD is a cytotoxic agent comprised non-alkylating group. Py-MPB-amino-C3-PBD acts as the payload for ADCs. Antimicrobial activity .

HY-N7057

Nonanoic acid Pelargonic acid; Pelargonic acid (n-Nonanoic acid, C9 )	Bacterial	Infection
Nonanoic acid is a naturally-occurring saturated fatty acid with nine carbon atoms. Nonanoic acid significantly reduces bacterial translocation, enhances antibacterial activity, and remarkably increases the secretion of porcine β-defensins 1 (pBD-1) and pBD-2 .

HY-124761

Poloppin	Polo-like Kinase (PLK) Autophagy	Cancer
Poloppin is a potent, cell penetrant inhibitor of the mitotic Polo-like kinase (PLK) (IC₅₀=26.9 μM) and prevents the protein-protein interaction via the Polo-box domain (PBD) (K_d= 29.5 μM). Poloppin selectively kills cells expressing mutant KRAS, enhancing death in mitosis. Poloppin is used for the study of KRAS-mutant cancers as single agents, or in combination with c-MET inhibitors .

HY-N7057S

Nonanoic acid-d17 Pelargonic acid-d₁₇	Bacterial
Nonanoic acid-d₁₇ is the deuterium labeled Nonanoic acid. Nonanoic acid is a naturally-occurring saturated fatty acid with nine carbon atoms. Nonanoic acid significantly reduces bacterial translocation, enhances antibacterial activity, and remarkably increases the secretion of porcine β-defensins 1 (pBD-1) and pBD-2[1].

HY-N7057S1

Nonanoic acid-d3 Pelargonic acid-d₃	Isotope-Labeled Compounds Bacterial
Nonanoic acid-d₃ is the deuterium labeled Nonanoic acid. Nonanoic acid is a naturally-occurring saturated fatty acid with nine carbon atoms. Nonanoic acid significantly reduces bacterial translocation, enhances antibacterial activity, and remarkably increases the secretion of porcine β-defensins 1 (pBD-1) and pBD-2[1].

HY-N7057S2

Nonanoic acid-d4 Pelargonic acid-d₄	Isotope-Labeled Compounds Bacterial
Nonanoic acid-d₄ is the deuterium labeled Nonanoic acid. Nonanoic acid is a naturally-occurring saturated fatty acid with nine carbon atoms. Nonanoic acid significantly reduces bacterial translocation, enhances antibacterial activity, and remarkably increases the secretion of porcine β-defensins 1 (pBD-1) and pBD-2[1].

HY-N7057S3

Nonanoic acid-d2 Pelargonic acid-d₂; Pelargonic acid-d2 (n-Nonanoic acid, C9 )	Bacterial	Infection
Nonanoic acid-d₂ is the deuterium labeled Nonanoic acid[1]. Nonanoic acid is a naturally-occurring saturated fatty acid with nine carbon atoms. Nonanoic acid significantly reduces bacterial translocation, enhances antibacterial activity, and remarkably increases the secretion of porcine β-defensins 1 (pBD-1) and pBD-2[2].

HY-107767

Antibiotic DC 81 DC 81	Antibiotic Apoptosis DNA/RNA Synthesis	Cancer
Antibiotic DC 81 (DC 81), an antitumor antibiotic produced by Streptomyces species, is a PBD (pyrrolo[2,1-c][1,4]benzodiazepine). Antibiotic DC 81 is potent inhibitor of nucleic acid synthesis. Antibiotic DC 81 can recognize and bind to specific sequences of DNA and form a labile covalent adduct .

HY-119173

PBD-150

Amyloid-β Neurological Disease

PBD-150 is a human glutaminyl cyclase (hQC) Y115E-Y117E variant inhibitor, with a K_i value of 490 nM .

PBD-150	Amyloid-β	Neurological Disease
PBD-150 is a human glutaminyl cyclase (hQC) Y115E-Y117E variant inhibitor, with a K_i value of 490 nM .

HY-126685

Mal-PEG4-VA-PBD	Drug-Linker Conjugates for ADC	Cancer
Mal-PEG4-VA-PBD is a agent-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via Mal-PEG4-VA.

HY-133433

DBCO-PEG4-VA-PBD	Drug-Linker Conjugates for ADC	Cancer
DBCO-PEG4-VA-PBD is a agent-linker conjugate for ADC by using the antitumor antibiotic, Pyrrolobenzodiazepine (PBD), linked via DBCO-PEG4-VA . DBCO-PEG4-VA-PBD is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-148424

PBD dimer-2	ADC Cytotoxin	Cancer
PBD dimer-2 (compound 2c) is a C8-linked pyrrolobenzodiazepine dimer. PBD dimer-2 can span an extra base pair and cross-link the 5′-Pu-GA(T/A)TC-Py sequence. PBD dimer-2 can be used as a payload for antibody–agent conjugates (ADCs), and it can be used for the research of cancer .

HY-160234

mc-vc-PAB-PBD

ADC Linker Cancer

mc-vc-PAB-PBD is a drug linker for the preparation of TDC and ADC .

mc-vc-PAB-PBD	ADC Linker	Cancer
mc-vc-PAB-PBD is a drug linker for the preparation of TDC and ADC .

HY-P2289

β-defesin 1 (pig) pBD-1	Bacterial	Infection
β-defesin 1 (pig) (pBD-1) is an endogenous and constitutively expressed antimicrobial peptide (AMP) from porcine tissues, particularly expresses in pig mucosal epithelial sites. β-defesin 1 (pig) has antimicrobial activities and contributes to mucosal and systemic host defenses in pigs .

HY-P2289A

β-defesin 1 (pig) (TFA) pBD-1 TFA	Bacterial	Infection
β-defesin 1 (pig) (pBD-1) TFA is an endogenous and constitutively expressed antimicrobial peptide (AMP) from porcine tissues, particularly expresses in pig mucosal epithelial sites. β-defesin 1 (pig) TFA has antimicrobial activities and contributes to mucosal and systemic host defenses in pigs .

HY-101127

SGD-1882

PBD dimer
ADC Cytotoxin Cancer

SGD-1882 is a cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, acting as the payload for ADCs.

SGD-1882 PBD dimer	ADC Cytotoxin	Cancer
SGD-1882 is a cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, acting as the payload for ADCs.

HY-102001

Tomaymycin DM	ADC Cytotoxin	Cancer
Tomaymycin DM, a DNA alkylator, is a derivative of Tomaymycin, it is a PBD dimer, which is attached to tumor targeting antibodies to create antibody-drug conjugates (ADCs).

HY-N9460

Sibiromycin	DNA Alkylator/Crosslinker Antibiotic	Cancer
Sibiromycin is a naturally produced glycosylated pyrrolobenzodiazepines (PBDs). Sibiromycin is also a potent antitumor antibiotic that binds covalently to DNA in the minor groove at the NH2 of guanine .

HY-101162

SGD-1910	Drug-Linker Conjugates for ADC	Cancer
SGD-1910 is a agent-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala .

HY-150036

Anthramycin	Antibiotic Cholecystokinin Receptor	Cancer
Anthramycin, a member of the pyrolobenzodiazepine (PBD) family, is a potent antibiotic. Anthramycin has potent antitumor activity. Anthramycin can act as an potent antagonist of cholecystokinin in the central nervous system in mice .

HY-136297

DGN549-C	Drug-Linker Conjugates for ADC	Cancer
DGN549-C consists a cleavable ADC linker valine-alanine (va) and PBD dimer. DGN549 is a novel DNA-alkylating cytotoxic payload and can be used in the synthesis of antibody-agent conjugates (ADCs) .

HY-24144

Tesirine intermediate-2	DNA Alkylator/Crosslinker	Cancer
Tesirine intermediate-2 is the intermediate of Tesirine (HY-128952). Tesirine (SG3249), a pyrrole benzodiazepine (PBD) dimer, is a DNA small channel crosslinker with strong cytotoxicity. Tesirine can be used to synthesize Antibody-Drug Conjugates (ADCs), the warhead component of the payload is SG3199 (HY-101161), which has strong anticancer cell activity.

HY-47820

Tesirine intermediate-1	DNA Alkylator/Crosslinker	Cancer
Tesirine intermediate-1 is the intermediate of Tesirine (HY-128952). Tesirine (SG3249), a pyrrole benzodiazepine (PBD) dimer, is a DNA small channel crosslinker with strong cytotoxicity. Tesirine can be used to synthesize Antibody-Drug Conjugates (ADCs), the warhead component of the payload is SG3199 (HY-101161), which has strong anticancer cell activity.

Cat. No.	Product Name

HY-L023

Toxins for Antibody-Drug Conjugate Research Library	92 compounds
Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide. The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 92 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Toxins for Antibody-Drug Conjugate Research Library

92 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 92 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Cat. No.	Product Name	Target	Research Area